Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16161213rdf:typepubmed:Citationlld:pubmed
pubmed-article:16161213lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16161213lifeskim:mentionsumls-concept:C0026769lld:lifeskim
pubmed-article:16161213lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:16161213lifeskim:mentionsumls-concept:C0026969lld:lifeskim
pubmed-article:16161213lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:16161213lifeskim:mentionsumls-concept:C0205178lld:lifeskim
pubmed-article:16161213lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:16161213lifeskim:mentionsumls-concept:C0178499lld:lifeskim
pubmed-article:16161213lifeskim:mentionsumls-concept:C1527178lld:lifeskim
pubmed-article:16161213pubmed:issue1-2lld:pubmed
pubmed-article:16161213pubmed:dateCreated2005-9-13lld:pubmed
pubmed-article:16161213pubmed:abstractTextWe investigated the apoptosis of myelin basic protein (MBP)-specific T lymphocytes in multiple sclerosis (MS) patients with acute (AMS) or stable (SMS) MS by evaluating the expression of apoptosis markers on peripheral cells. Cells of healthy controls (HC) were evaluated as well. Results showed that mitogen-stimulated apoptosis was comparable among patients and controls, whereas MBP-stimulated CD4+ and CD8+ 7-AAD+ and 7-AAD+ Fas+ cell (apoptotic cells) were significantly reduced in AMS patients. A reduction of the apoptotic rate of myelin-specific CD4+ and CD8+ T lymphocytes could be involved in the immune-mediated destruction of the myelin sheath seen in AMS patients.lld:pubmed
pubmed-article:16161213pubmed:languageenglld:pubmed
pubmed-article:16161213pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16161213pubmed:citationSubsetIMlld:pubmed
pubmed-article:16161213pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16161213pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16161213pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16161213pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16161213pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16161213pubmed:statusMEDLINElld:pubmed
pubmed-article:16161213pubmed:monthSeplld:pubmed
pubmed-article:16161213pubmed:issn0165-5728lld:pubmed
pubmed-article:16161213pubmed:authorpubmed-author:ClericiMarioMlld:pubmed
pubmed-article:16161213pubmed:authorpubmed-author:FilippiMassim...lld:pubmed
pubmed-article:16161213pubmed:authorpubmed-author:TrabattoniDar...lld:pubmed
pubmed-article:16161213pubmed:authorpubmed-author:CaputoDomenic...lld:pubmed
pubmed-article:16161213pubmed:authorpubmed-author:FerrantePasqu...lld:pubmed
pubmed-article:16161213pubmed:authorpubmed-author:SpecialeLivia...lld:pubmed
pubmed-article:16161213pubmed:authorpubmed-author:SaresellaMari...lld:pubmed
pubmed-article:16161213pubmed:authorpubmed-author:RuzzanteStefa...lld:pubmed
pubmed-article:16161213pubmed:authorpubmed-author:Della...lld:pubmed
pubmed-article:16161213pubmed:authorpubmed-author:FasanoFrances...lld:pubmed
pubmed-article:16161213pubmed:authorpubmed-author:CavarrettaRos...lld:pubmed
pubmed-article:16161213pubmed:authorpubmed-author:MarventanoIva...lld:pubmed
pubmed-article:16161213pubmed:issnTypePrintlld:pubmed
pubmed-article:16161213pubmed:volume166lld:pubmed
pubmed-article:16161213pubmed:ownerNLMlld:pubmed
pubmed-article:16161213pubmed:authorsCompleteYlld:pubmed
pubmed-article:16161213pubmed:pagination173-9lld:pubmed
pubmed-article:16161213pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:meshHeadingpubmed-meshheading:16161213...lld:pubmed
pubmed-article:16161213pubmed:year2005lld:pubmed
pubmed-article:16161213pubmed:articleTitleProgrammed cell death of myelin basic protein-specific T lymphocytes is reduced in patients with acute multiple sclerosis.lld:pubmed
pubmed-article:16161213pubmed:affiliationLaboratory of Molecular Medicine and Biotechnology, IRCCS S. Maria Nascente, Don C. Gnocchi Foundation, 66, Milan, Italy.lld:pubmed
pubmed-article:16161213pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16161213pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16161213lld:pubmed